MDRT + ADT for Prostate Cancer

Recruiting at 1 trial location

Overseen By Angela Y Jia, MD, PhD

Age: 18+

Sex: Male

Trial Phase: Phase 2

Sponsor: Case Comprehensive Cancer Center

Must be taking: Hormone therapy

Must not be taking: Investigational agents

Disqualifiers: Castration resistant, Visceral metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 5 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 12 months

200 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine whether adding metastasis-directed radiotherapy (MDRT) to the usual hormone therapy for prostate cancer can better control the disease when it has spread beyond the prostate. Typically, hormone therapy, sometimes combined with prostate-targeted radiation, treats prostate cancer that has spread. This study tests whether directing radiation at cancer in other areas makes a difference. Men newly diagnosed with prostate cancer that has spread to 1-5 areas outside the pelvis, who haven't yet received treatment for these, might be a good fit for this trial. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, it mentions that participants will receive hormone therapy for 12 months, which is the standard treatment for prostate cancer.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that metastasis-directed radiotherapy (MDRT) for prostate cancer is generally easy for patients to handle. Studies have found that side effects are usually mild and manageable. A recent review of several studies examined the addition of focused radiation to treat cancer that has spread. The results suggested that patients did not experience severe side effects more often than those who did not receive the extra radiation.

Additionally, androgen deprivation therapy (ADT), already approved by the FDA for treating prostate cancer, is considered safe for most patients. Common side effects might include hot flashes, tiredness, and mood changes, but these are usually not severe.

Overall, both MDRT and ADT have been studied and found to be fairly safe for treating prostate cancer, with most side effects being mild and manageable. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about the combination of MDRT (metastasis-directed radiotherapy) with the standard of care for prostate cancer because it offers a targeted approach to treating de novo oligometastatic prostate cancer. Unlike standard treatments that involve systemic therapies and local therapies like radiotherapy or surgery, MDRT specifically targets metastatic sites, potentially improving precision and outcomes. This method could lead to more effective management of metastases while minimizing harm to surrounding healthy tissue. Moreover, by adding MDRT to the standard regimen, there's hope for enhancing the overall effectiveness of treatment, reducing the recurrence rate, and potentially improving survival rates for patients.

What evidence suggests that this trial's treatments could be effective for prostate cancer?

Research shows that metastasis-directed radiotherapy (MDRT), a type of targeted radiation treatment for prostate cancer that has spread, is promising. In this trial, one group of participants will receive the standard of care plus MDRT. Studies have found that MDRT can delay the need for further treatments and reduce reliance on hormone therapy. For instance, patients receiving MDRT often experience a longer period before requiring additional systemic treatments. This method targets cancer in specific areas, potentially slowing the disease. Early results also suggest that MDRT is generally safe with few side effects. Overall, MDRT appears to improve disease control for those with limited prostate cancer spread. ^{1 2 3 6 7}

Who Is on the Research Team?

Angela Y Jia, MD, PhD

Principal Investigator

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Daniel E Spratt, MD

Principal Investigator

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Are You a Good Fit for This Trial?

Men over 18 with newly diagnosed metastatic prostate cancer, who haven't had prior treatment for it and are fit enough for therapy (ECOG ≤1). They should have evidence of limited spread on scans and be able to start hormone therapy. Excluded are those with resistant cancer, other active cancers within 2 years, or serious health issues that could interfere with the study.

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent

My scans show 1-5 cancer spread areas in bones or lymph nodes outside the pelvis.

I am fully active and can carry on all pre-disease activities without restriction.

Exclusion Criteria

Participant is participating in a concurrent treatment protocol for cancer

Any condition that in the opinion of the investigator would preclude participation in this study

I have had treatment aimed at curing my prostate cancer.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive hormone therapy for 12 months and may undergo radiotherapy or surgery. A portion will receive metastasis-directed radiotherapy (MDRT).

12 months

Multiple visits for treatment administration

Follow-up

Participants are monitored for safety and effectiveness after treatment, with follow-up by their doctor for up to five years.

5 years

What Are the Treatments Tested in This Trial?

Interventions

• Androgen deprivation therapy (ADT)
• Metastasis directed radiotherapy (MDRT)

Trial Overview

The trial is testing if adding radiation (MDRT) to areas where prostate cancer has spread improves disease control compared to usual treatments alone. Usual care includes lifelong hormone therapy and possibly prostate RT or surgery. Participants will be randomly chosen to receive either standard care or standard plus MDRT.

How Is the Trial Designed?

Group I: SOC + MDRT Experimental Treatment 4 Interventions

* Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy \[RT\] or radical prostatectomy \[RP\]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm. * SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20. * MDRT should be completed by the end of Week 24. Depending on the participant, there are different approaches to MDRT dosing and fraction size.

Group II: Standard of Care (SOC) Active Control 3 Interventions

* Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy \[RT\] or radical prostatectomy \[RP\]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm. * SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20.

Androgen deprivation therapy (ADT) is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:

Approved in European Union as Androgen deprivation therapy for:

• Prostate cancer
• Metastatic prostate cancer
• Locally advanced prostate cancer

Approved in United States as Androgen deprivation therapy for:

• Prostate cancer
• Metastatic prostate cancer
• Locally advanced prostate cancer

Approved in Canada as Androgen deprivation therapy for:

• Prostate cancer
• Metastatic prostate cancer
• Locally advanced prostate cancer

Approved in Japan as Androgen deprivation therapy for:

• Prostate cancer
• Metastatic prostate cancer
• Locally advanced prostate cancer

Approved in Switzerland as Androgen deprivation therapy for:

• Prostate cancer
• Metastatic prostate cancer
• Locally advanced prostate cancer

Who Is Running the Clinical Trial?

Case Comprehensive Cancer Center

Lead Sponsor

Trials

472

Recruited

33,400+

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

Published Research Related to This Trial

Androgen deprivation therapy (ADT), particularly using GnRH-agonists and GnRH-antagonists like leuprolide, degarelix, and relugolix, is effective in suppressing testosterone levels in prostate cancer treatment, with similar efficacy across these methods.

Oral relugolix may offer improved cardiovascular safety compared to other ADT options, although this finding is based on secondary analyses and should be interpreted cautiously.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Advances with androgen deprivation therapy for prostate cancer. Yu, EM., Aragon-Ching, JB.[2022]

Androgen deprivation therapy (ADT) is a key treatment for prostate cancer, but the best timing, duration, and type of ADT are still being researched.

Current first-line treatments include orchiectomy, LHRH agonists, and combined androgen blockade (CAB), with new combinations showing potential for better outcomes and reduced side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The truth is out there: an overall perspective on androgen deprivation. Hellerstedt, BA., Pienta, KJ.[2019]

A systematic review of 4141 patients from 8 randomized trials found that androgen deprivation therapy (ADT) does not increase the risk of cardiovascular death in men with unfavorable-risk, nonmetastatic prostate cancer.

ADT was associated with a significant reduction in prostate cancer-specific mortality (PCSM) and all-cause mortality, indicating it may improve overall survival outcomes for these patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Nguyen, PL., Je, Y., Schutz, FA., et al.[2022]

In a study of 373 intermediate-risk prostate cancer patients treated with radiotherapy over 14 years, those aged 70 or younger who received radiotherapy alone had a higher risk of biochemical failure compared to those who received combined radiotherapy and androgen deprivation therapy (ADT).

The results suggest that short-term ADT may be beneficial for younger patients with favorable intermediate-risk prostate cancer, as it improved biochemical relapse-free survival from 82.1% to 94.0% compared to radiotherapy alone.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer? Amit, U., Lawrence, YR., Weiss, I., et al.[2020]

Androgen deprivation therapy (ADT) combined with radiation therapy (RT) results in higher quality-adjusted life years (QALYs) compared to RT alone, indicating a better overall survival outcome despite potential increased toxicity from ADT.

Using two different analysis methods, QASAD and QASAP, the study found that RT + ADT provided slightly better quality-adjusted survival, suggesting that these methods can aid in making treatment decisions that balance survival benefits with quality of life considerations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparative quality-adjusted survival analysis between radiation therapy alone and radiation with androgen deprivation therapy in patients with locally advanced prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 85-31 with novel decision analysis methods. Ahn, S., Lee, M., Jeong, CW.[2022]

Current guidelines for androgen-deprivation therapy (ADT) in advanced prostate cancer set a testosterone target of <50 ng/dL, but emerging evidence suggests that a lower target of <20 ng/dL may be more prognostically relevant.

Despite the growing data supporting lower testosterone levels during ADT, there are no established clinical recommendations for measuring testosterone in routine practice, highlighting a gap in current treatment protocols.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Management of testosterone in advanced hormone-sensitive prostate cancer: still up to date?] Zastrow, S., Mudra, TN., Suttmann, H.[2022]

Androgen deprivation therapy (ADT) is effective for managing symptoms of prostate cancer but can lead to significant side effects that worsen over time, and it does not improve survival in men with localized disease.

Neoadjuvant ADT combined with external beam radiation has been shown to enhance survival in men with locally advanced prostate cancer, while immediate adjuvant ADT does not provide benefits for most men after radical prostatectomy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence. Ginzburg, S., Albertsen, PC.[2019]

Androgen deprivation therapy (ADT) significantly enhances biochemical control when combined with dose-escalated radiation therapy (RT) for prostate cancer, as supported by recent phase III studies.

There is now randomized evidence supporting the use of ADT alongside RT in patients who have undergone prostatectomy, highlighting its ongoing importance in prostate cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update. Kauffmann, G., Liauw, SL.[2018]

Androgen deprivation therapy (ADT) is a key treatment for prostate cancer, enhancing the effectiveness of local therapies like radiation and providing significant relief for metastatic cases.

While ADT is effective, it can lead to adverse effects such as hot flashes, decreased bone density, metabolic changes, and gynecomastia, which require careful management and ongoing research to address.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Management of the side effects of androgen deprivation therapy in men with prostate cancer. Flaig, TW., Glodé, LM.[2019]

Androgen deprivation therapy (ADT) is effective for managing metastatic or recurrent prostate cancer but can lead to significant side effects, including changes in body composition, increased fracture risk, and insulin resistance.

Recent studies suggest that denosumab and toremifene citrate can help reduce fracture risk in men undergoing ADT, highlighting the importance of managing these adverse effects to improve patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Kim, HS., Freedland, SJ.[2015]

In a study of 992 prostate cancer patients, longer durations of androgen deprivation therapy (ADT) significantly improved overall survival for patients with Gleason grade group (GG) 4, while lifelong ADT was more beneficial for those with GG 5 disease.

The findings suggest that while both GG 4 and GG 5 patients benefit from ADT, the optimal duration of treatment differs, indicating a need for tailored approaches to maximize efficacy and minimize treatment duration.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. Kishan, AU., Wang, X., Seiferheld, W., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11654405/

Stereotactic body radiotherapy as metastasis-directed therapy ...

We aimed to evaluate the efficacy and safety of SBRT as metastasis-directed therapy (MDT) in oligometastatic prostate cancer (OMPC) compared to no MDT reported ...

2.

ascopubs.org

ascopubs.org/doi/10.1200/GO-25-00004

Metastasis-Directed Stereotactic Body Radiation Therapy ...

Time to next systemic therapy after stereotactic body radiation therapy for oligoprogressive metastatic castrate-resistant prostate cancer.

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10990008/

Stereotactic ablative radiation therapy in metastatic ...

Treating omPCa with SABR MDT appears to generate an efficacy signal with minimal morbidity across both hormone-sensitive and castration-resistant disease.

4.

sciencedirect.com

sciencedirect.com/science/article/pii/S0167814025052235

Stereotactic ablative body radiotherapy for PSMA-PET/CT ...

This is the largest cohort of PSMA PET staged patients undergoing SABR for omPC, effective in delaying treatment escalation and ADT exposure ...

5.

urotoday.com

urotoday.com/conference-highlights/sociedad-colombiana-de-urologia-scu-colombia-2025/162645-scu-2025-low-volume-hormone-sensitive-metastatic-disease-metastasis-directed-therapy-in-favor.html

SCU 2025: Low-Volume Hormone-Sensitive Metastatic ...

Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. Int J Cancer. 2024 ...

6.

astro.org

astro.org/news-and-publications/news-and-media-center/news-releases/2025/radiopharmaceutical-added-to-stereotactic-radiation-delays-prostate-cancer-progression-in-patients-w

Radiopharmaceutical added to stereotactic radiation ...

Randomized trial finds PSMA-targeting agent paired with metastasis-directed radiation therapy doubled progression-free survival.

7.

advancesradonc.org

advancesradonc.org/article/S2452-1094(25)00084-3/fulltext

Efficacy and Safety of Metastatic Directed Treatment ...

We report a meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of adding stereotactic radiation to metastases ...